Brolucizumab stabilizes retinal exudation and fluid, improving visual outcomes in wet AMD management. Study showed BCVA and CRT improvements at 6 and 12 months, with minimal adverse events. Small ...
Age-related macular degeneration (AMD) is a leading cause of vision loss among people aged 50 and older. While treatments for the wet form of AMD have shown promise, the dry form, which accounts for ...
The last time I spoke about REGENXBIO (RGNX), it was with respect to a Seeking Alpha article entitled "Regenxbio: With Additional MPS II Data, Program Advancement Remains On Track". With respect to ...
AMD primarily affects central vision, complicating activities like reading and driving, but does not cause complete blindness. Wet AMD involves abnormal blood vessel growth, while dry AMD progresses ...
Manassas, Virginia--(Newsfile Corp. - July 9, 2025) - Notal Vision, a digital healthcare provider advancing remote patient monitoring in ophthalmology, announced the publication of pivotal study data ...
It would be devastating to lose your eyesight to macular degeneration. Age-related macular degeneration (AMD) is a progressive eye disease that affects those over the age of 50. There is ...
Hosted on MSN
Light therapy for dry AMD: What do we know?
Armed with a recent authorization from the FDA, eye specialists are offering light therapy to patients with non-exudative (dry) age-related macular degeneration (AMD), aiming to stop or even reverse ...
HAYWARD, Calif., Feb. 3, 2025 /PRNewswire/ — Avirmax Biopharma, Inc., a leader in the development of the next generation of AAV gene therapies, today announced completion of the first cohort of the ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The wet AMD patient never lives in ...
Newmedica Oxfordshire is highlighting the signs of age-related macular degeneration (AMD) during AMD Awareness Month and is calling for the NHS to publish clearer data on its waiting lists for AMD ...
PARIS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results